(Total Views: 130)
Posted On: 04/30/2020 3:39:49 PM
Post# of 25780
$CURR 2.03x2.08 Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions
Equipment manufacturers, cannabis processors and drug developers can license CURE’s patented methods for optimal extraction of cannabinoids
LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents represent an expansion of CURE’s existing “product by process” patents for obtaining multiple unique cannabis concentrates using super critical fluid extraction (SCFE). These include cannabinoid concentrates enriched in cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), a non-psychoactive cannabinoid which has shown promising therapeutic activity in animal studies in areas such as inflammatory bowel disease, cancer and infectious diseases.
https://finance.yahoo.com/news/cure-pharmaceu...10067.html
Equipment manufacturers, cannabis processors and drug developers can license CURE’s patented methods for optimal extraction of cannabinoids
LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents represent an expansion of CURE’s existing “product by process” patents for obtaining multiple unique cannabis concentrates using super critical fluid extraction (SCFE). These include cannabinoid concentrates enriched in cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), a non-psychoactive cannabinoid which has shown promising therapeutic activity in animal studies in areas such as inflammatory bowel disease, cancer and infectious diseases.
https://finance.yahoo.com/news/cure-pharmaceu...10067.html
(0)
(0)
